Molibresib (I-BET-762)

For research use only.

Catalog No.S7189 Synonyms: GSK525762, GSK525762A

21 publications

Molibresib (I-BET-762) Chemical Structure

CAS No. 1260907-17-2

Molibresib (I-BET-762, GSK525762, GSK525762A) is an inhibitor for BET proteins with IC50 of ~35 nM in a cell-free assay, suppresses the production of proinflammatory proteins by macrophages and blocks acute inflammation, highly selective over other bromodomain-containing proteins.

Selleck's Molibresib (I-BET-762) has been cited by 21 publications

Purity & Quality Control

Choose Selective Epigenetic Reader Domain Inhibitors

Biological Activity

Description Molibresib (I-BET-762, GSK525762, GSK525762A) is an inhibitor for BET proteins with IC50 of ~35 nM in a cell-free assay, suppresses the production of proinflammatory proteins by macrophages and blocks acute inflammation, highly selective over other bromodomain-containing proteins.
Targets
BET proteins [1]
(Cell-free assay)
35 nM
In vitro

I-BET-762 is an inhibitor for BET (bromodomain and extra terminal domain) proteins, BRD2, BRD3 and BRD4, binds to the tandem bromodomains of BET with Kd of 50.5–61.3 nM, displaces a tetra-acetylated H4 peptide prebound to tandem bromodomains of BET with IC50 of 32.5–42.5 nM in FRET analysis. I-BET-762 occupies the acetyl-lysine binding pocket of BET proteins and inhibits binding of BET proteins to acetylated histones, thus disrupts the formation of the chromatin complexes essential for expression of inflammatory genes. [1] I-BET-762 treatment during the first 2 d of differentiation alters CD4+ T-cell cytokine production, up-regulated expression of several antiinflammatory gene products and down-regulated expression of several proinflammatory cytokines. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HepG2 MmnUSpVv[3Srb36gZZN{[Xl? MlzJNVghcHK| NXnjWocyUW6mdXP0bY9vKG:oIHj1cYFvKEGyb1GxJIdmdmViZYjwdoV{e2mxbjDpckB{fGGkbImgeJJidnOoZXP0[YQhcHWvYX6gTIVxTzJiY3XscJMh[2:neIDy[ZN{cW6pIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjZoTldkAyQCCqcoOgZpkhdHWvaX7ld4NmdmOnIHHzd4F6NCCHQ{WwJF0hOC55IN88UU4> MlHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF3NkizNlIoRjJzNU[4N|IzRC:jPh?=
HepG2 MUTGeY5kfGmxbjDhd5NigQ>? Mn;YOkBpenN? M3P4TGlv\HWldHnvckBw\iCqdX3hckBCeG:DMTDwdo91\WmwIIP5cpRp\XOrczDpckBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyCwZX;zfY51cGW|aYPl[EBz[WSrb3zhZoVt\WRicILveIVqdiC|ZXPy[ZRqd25iYX\0[ZIhPiCqcoOgZpkhW0SVIGDBS2Uh[W6jbInzbZMhcW5icILld4Vv[2Vib3[gX|M2W12vZYTobY9vcW6n NIHzNWY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUW2PFMzOid-MkG1Olg{OjJ:L3G+
HepG2 M13i[2Z2dmO2aX;uJIF{e2G7 NXHrXlhwOThiaILz M2nHeXVxemWpdXzheIlwdiCxZjDBdI9COSCneIDy[ZN{cW:wIHnuJIh2dWGwIFjldGczKGOnbHzzJIF{e2W|c3XkJIF{KGOxbnPlcpRz[XSrb36gdoVyfWm{ZXSgeI8hcW6lcnXhd4UhPzBnIH;mJIx2[2moZYLhd4Uh[WO2aY\peJkh[W[2ZYKgNVghcHK|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiRVOxO|AhRSByLkKg{txONg>? NUeyNIZsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzPFY2OjlpPkKyN|g3PTJ7PD;hQi=>
HepG2 NUnsTFB4TnWwY4Tpc44h[XO|YYm= MWGxPEBpenN? NY\he3JUUW6mdXP0bY9vKG:oIHj1cYFvKEGyb1GxJIdmdmViZYjwdoV{e2mxbjDpckB{fGGkbImgeJJidnOoZXP0[YQhcHWvYX6gTIVxTzJiY3XscJMh[2:neIDy[ZN{cW6pIHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjZoTldkAyQCCqcoOgZpkhdHWvaX7ld4NmdmOnIHHzd4F6NCCHQ{WwJF0hOC55IN88UU4> M3vuWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUK0OFM1Lz5{MkmyOFQ{PDxxYU6=
PBMC MkKzRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>? NYjP[WpvSW62aXnu[oxidW2jdH;yfUBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDCUWMh[2WubIOgZZN{\XO|ZXSgZZMhVFCVLXnu[JVk\WRiSVytOkBxem:mdXP0bY9vKGK7IHPo[Y1qdHWvaX7ld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC5|MU[yN{DPxE1w NYG1W3dDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwNVU6PjdpPkK0NFE2QTZ5PD;hQi=>
Raji NVnjR3NYTnWwY4Tpc44h[XO|YYm= MlvqOEBpenN? M4GxPWlvcGmkaYTpc44hd2ZiQmLEOEBqdiCqdX3hckBT[WqrIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDv[kBOYUNiZYjwdoV{e2mxbjDh[pRmeiB2IHjyd{whUUN3MDC9JFAvOTlizszNMi=> MkXSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC3OVgoRjJ2OUCwO|U5RC:jPh?=
Rosetta2 DE3 NXXsPXp5TnWwY4Tpc44h[XO|YYm= NWrjTFJyOzBibXnudy=> M13FPWRqe3CuYXPlcYVvfCCxZjDGRW0udGGkZXzl[EBbSkF{NEig[pJwdSCEUlSzJGJFOiBqM{C2JJRwKDRzNzDhcYlvdyCjY3nkJJJme2mmdXXzLUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG|c3H5MEBMcSB;IECuNFMxOyEQvF2u M2X1flxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3 M123ZWZ2dmO2aX;uJIF{e2G7 NFXJOm4{OCCvaX7z M1LDT2Rqe3CuYXPlcYVvfCCxZjDGRW0udGGkZXzl[EBbSkF{NEig[pJwdSCEUlS0JGJFOiBqM{OzJJRwKDR4MDDhcYlvdyCjY3nkJJJme2mmdXXzLUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG|c3H5MEBMcSB;IECuNFMzOyEQvF2u Ml3zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3 MnrXSpVv[3Srb36gZZN{[Xl? M4DLcVMxKG2rboO= NEjpXGFFcXOybHHj[Y1mdnRib3[gSmFONWyjYnXs[YQhYkKDMkS4JIZzd21iQmLEOEBDTDFiKES0JJRwKDF4ODDhcYlvdyCjY3nkJJJme2mmdXXzLUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG|c3H5MEBMcSB;IECuNFM5QCEQvF2u M4DWZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3 NUn4bZZ7TnWwY4Tpc44h[XO|YYm= NWjUZYhXSmmwZHnu[{Bi\m[rbnn0fUB1dyCkaX;0bY56dGG2ZXSgRnJFOyCEREKgLFMxPiC2bzC0NVch[W2rbn:gZYNq\CC{ZYPp[JVmeyliKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gVo9{\XS2YUKgSGU{KGOnbHzzJIJ6KGKrbz3sZZlmeiCrboTldoZmem:vZYTyfUBu\XSqb3SsJGtlKD1iMD6wOFA4KM7:TT6= MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3 MljISpVv[3Srb36gZZN{[Xl? NUfXbXFNSmmwZHnu[{Bi\m[rbnn0fUB1dyCkaX;0bY56dGG2ZXSgRnJFOiCEREKgLFM1QSC2bzC0OlAh[W2rbn:gZYNq\CC{ZYPp[JVmeyliKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gVo9{\XS2YUKgSGU{KGOnbHzzJIJ6KGKrbz3sZZlmeiCrboTldoZmem:vZYTyfUBu\XSqb3SsJGtlKD1iMD6wOFU1KM7:TT6= MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB6MEC2OEc,OjZyOECwOlQ9N2F-
Rosetta2 DE3 MlmySpVv[3Srb36gZZN{[Xl? NYHzfW1sSmmwZHnu[{Bi\m[rbnn0fUB1dyCkaX;0bY56dGG2ZXSgRnJFPCCEREKgLFM{OyC2bzC0OlAh[W2rbn:gZYNq\CC{ZYPp[JVmeyliKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gVo9{\XS2YUKgSGU{KGOnbHzzJIJ6KGKrbz3sZZlmeiCrboTldoZmem:vZYTyfUBu\XSqb3SsJGtlKD1iMD6wOFc3KM7:TT6= Mkf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyOECwOlQoRjJ4MEiwNFY1RC:jPh?=
Rosetta2 DE3 NHnlOFdHfW6ldHnvckBie3OjeR?= MnH5N|AhdWmwcx?= M{jJeWRqe3CuYXPlcYVvfCCxZjDGRW0udGGkZXzl[EBbSkF{NEig[pJwdSCEUlSyJGJFOiBqM{S5JJRwKDR4MDDhcYlvdyCjY3nkJJJme2mmdXXzLUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG|c3H5MEBMcSB;IECuNFQ6OiEQvF2u NFzze5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3 NECzdIxHfW6ldHnvckBie3OjeR?= NIjPSYQ{OCCvaX7z NG\6T2JFcXOybHHj[Y1mdnRib3[gSmFONWyjYnXs[YQhYkKDMkS4JIZzd21iQmLEN{BDTDFiKEK0JJRwKDF2NDDhcYlvdyCjY3nkJJJme2mmdXXzLUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCobIXvdoV{[2WwY3WgdI9t[XKrenH0bY9vKGG|c3H5MEBMcSB;IECuNFU{QSEQvF2u NFvFWpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3 MYTGeY5kfGmxbjDhd5NigQ>? NGTLW4M{OCCvaX7z MWHEbZNxdGGlZX3lcpQhd2ZiRlHNMYxi[mWuZXSgXmJCOjR6IH\yc40hSlKGMjDCSFEhMDd{IITvJFIxPSCjbXnuc{Bi[2mmIILld4llfWW|KTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBTd3OndIThNkBFTTNiY3XscJMh[W[2ZYKgN|AhdWmwczDifUBndHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7LDDLbUA:KDBwMEW2PEDPxE1w NFXrTo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3 MVLGeY5kfGmxbjDhd5NigQ>? MWLCbY5lcW6pIHHm[olvcXS7IITvJIJqd3SrbonsZZRm\CCEUlSzJGJFOSBqMkSgeI8hOTR2IHHtbY5wKGGlaXSgdoV{cWS3ZYOpJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW|c3XkJIlvKFKxc3X0eIEzKESHMzDj[YxteyCkeTDibY8udGG7ZYKgbY51\XKoZYLvcYV1enlibXX0bI9lNCCNZDC9JFAvODZyNzFOwG0v NEfYepA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
MV4-11 NYLaTWZ7S3m2b4TvfIlkcXS7IHHzd4F6 MUm0JIRigXN? MmLaR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXY1NTFzIHPlcIx{KGijcnLvdolv\yCPTFyxJIZ2e2mxbjDn[Y5mKGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDRiZHH5d{BjgSCFZXzsWIl1\XJvR3zvJIx2dWmwZYPj[Y51KGG|c3H5MEBKSzVyIE2gNE4xQTNizszNMi=> NUPZc4JmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
Rosetta2 DE3 M3:xb2Z2dmO2aX;uJIF{e2G7 NYq1N|B3OzBibXnudy=> NXfnPYFlTGm|cHzhZ4Vu\W62IH;mJGZCVS2uYXLlcIVlKFqEQUK0PEBnem:vIFLSSFQhSkR{IDizN|MhfG9iNE[wJIFucW6xIHHjbYQhemW|aXT1[ZMqKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGLvd4V1fGF{IFTFN{Bk\WyuczDh[pRmeiB|MDDtbY5{KGK7IH\seY9z\XOlZX7j[UBxd2yjcnn6ZZRqd25iYYPzZZktKEmFNUCgQUAxNjB7OESg{txONg>? NFnNUlY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3 MYHGeY5kfGmxbjDhd5NigQ>? NWXJXVl2SmmwZHnu[{Bi\m[rbnn0fUB1dyCkaX;0bY56dGG2ZXSgRnJFPCCEREGgLFQ1KHSxIEG2PEBidWmwbzDhZ4llKHKnc3nkeYV{MSBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDSc5NmfHSjMjDESVMh[2WubIOgZpkh[mmxLXzhfYVzKGmwdHXy[oVzd22ndIL5JI1mfGixZDygT4QhRSByLkC5PVQh|ryPLh?= NGfLd|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkC4NFA3PCd-Mk[wPFAxPjR:L3G+
Rosetta2 DE3 M1PrXGZ2dmO2aX;uJIF{e2G7 NWHqO5F{OzBibXnudy=> MVvEbZNxdGGlZX3lcpQhd2ZiRlHNMYxi[mWuZXSgXmJCOjR6IH\yc40hSlKGNDDCSFEhMDR2IITvJFE3QCCjbXnuc{Bi[2mmIILld4llfWW|KTCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBTd3OndIThNkBFTTNiY3XscJMh[W[2ZYKgN|AhdWmwczDifUBndHWxcnXzZ4Vv[2VicH;sZZJqgmG2aX;uJIF{e2G7LDDJR|UxKD1iMD6xOVYh|ryPLh?= M2TmVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
Rosetta2 DE3 MV\GeY5kfGmxbjDhd5NigQ>? NHP3XlNDcW6maX7nJIFn\mmwaYT5JJRwKGKrb4Tpcplt[XSnZDDCVmQzKEKGMTCoO|IhfG9iMkC1JIFucW6xIHHjbYQhemW|aXT1[ZMqKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGLvd4V1fGF{IFTFN{Bk\WyuczDifUBjcW9vbHH5[ZIhcW62ZYLm[ZJwdWW2comgcYV1cG:mLDDL[EA:KDBwMUW5JO69VS5? M{ezPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEiwNFY1Lz5{NkC4NFA3PDxxYU6=
MOLM13 NHf0eIpEgXSxdH;4bYNqfHliYYPzZZk> NFvWWG41KGSjeYO= NU[yWJVFS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVU:OTUGzJINmdGy|IHjhdoJwemmwZzDNUGwyKG[3c3nvckBo\W6nIHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IESg[IF6eyCkeTDD[YxtXGm2ZYKtS4xwKGy3bXnu[ZNk\W62IHHzd4F6NCCLQ{WwJF0hOC5{NEGg{txONg>? NVvCNlc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wPFAxPjRpPkK2NFgxODZ2PD;hQi=>
BL21(DE3) MUnGeY5kfGmxbjDhd5NigQ>? Mo\JRolv\GmwZzDh[oZqdmm2eTD0c{BPNXSncn3pcoFtKEirc{[teIFo\2WmLVLSSFQh[nKxbX;kc41icW5iMjCoeY5sdm:5bjDvdolocW5rIHX4dJJme3OnZDDpckBkd22yZYTlcpQhTXOlaHXybYNpcWFiY3;sbUBDVDJzKFTFN{kh[2WubIOgZpkhcXOxdHjldo1idCC2aYTyZZRqd25iY3Hsc5JqdWW2comsJGtlKD1iMD6wOlUh|ryPLh?= M4T0U|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4M{[3OVM6Lz5{NkO2O|U{QTxxYU6=
BL21(DE3) NW\XUoFYTnWwY4Tpc44h[XO|YYm= NU\rbHBqSmmwZHnu[{Bi\m[rbnn0fUB1dyCQLYTldo1qdmGuIFjpd|YufGGpZ3XkMWJTTDRiYoLvcY9ld22jaX6gNUApfW6tbn;3ckBwemmpaX6pJIV5eHKnc4Pl[EBqdiClb33w[ZRmdnRiRYPjbIVzcWOqaXGgZ49tcSCETEKxLGRGOyliY3XscJMh[nliaYPveIhmem2jbDD0bZRz[XSrb36gZ4Ftd3KrbXX0dpktKEumIE2gNE4xQTVizszNMi=> NEW5XpA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO2O|U{QSd-Mk[zOlc2Ozl:L3G+
BL21(DE3) NFvFTGtHfW6ldHnvckBie3OjeR?= NXvkVFB2SmmwZHnu[{Bi\m[rbnn0fUB1dyCodXzsJIxmdme2aDDOMZRmem2rbnHsJGhqezZvdHHn[4VlNUKUREKgZpJwdW:mb33hbY4hOiBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDjc41x\XSnboSgSZNkcGW{aXPobYEh[2:uaTDCUFIyMESHMzmgZ4VtdHNiYomgbZNwfGincn3hcEB1cXS{YYTpc44h[2Gub4LpcYV1enluIFvkJF0hOC5zIN88UU4> NXHHeodIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[zOlc2OzlpPkK2N|Y4PTN7PD;hQi=>
BL21(DE3) MYLGeY5kfGmxbjDhd5NigQ>? M4XJZmJqdmSrbnegZYZncW6rdImgeI8h\nWubDDs[Y5ofGhiTj30[ZJucW6jbDDIbZM3NXSjZ3fl[E1DWkR{IHLyc41w\G:vYXnuJFEhMHWwa37ve44hd3KrZ3nuLUBmgHC{ZYPz[YQhcW5iY3;tdIV1\W62IFXzZ4hmemmlaHnhJINwdGliQlyyNUhFTTNrIHPlcIx{KGK7IHnzc5Rp\XKvYXygeIl1emG2aX;uJINidG:{aX3leJJ6NCCNZDC9JFAvOjNizszNMi=> MlrDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ|Nke1N|koRjJ4M{[3OVM6RC:jPh?=
BL21(DE3)-R3-pRARE2 MlL2SpVv[3Srb36gZZN{[Xl? NV:3WWo5UW6qaXLpeIlwdiCxZjDoeY1idiCKaYOteIFo\2WmIFLSSFQh[nKxbX;kc41icW5iMjDlfJBz\XO|ZXSgbY4hTXOlaHXybYNpcWFiY3;sbUBDVDJzKFTFN{kuWjNvcGLBVmUzKGOnbHzzJIJ6KE[URWSgZZN{[XluIFnDOVAhRSByLkCzOkDPxE1w NV\nfXFDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[3N|E1QTBpPkK2O|MyPDlyPD;hQi=>
BL21(DE3)-R3-pRARE2 MVXGeY5kfGmxbjDhd5NigQ>? MlLZTY5pcWKrdHnvckBw\iCqdX3hckBJcXNvdHHn[4VlKEKURESgZpJwdW:mb33hbY4hOSCneIDy[ZN{\WRiaX6gSZNkcGW{aXPobYEh[2:uaTDCUFIyMESHMzmtVlMueFKDUlWyJINmdGy|IHL5JGZTTVRiYYPzZZktKEmFNUCgQUAxNjB|NjFOwG0v MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd|MUS5NEc,OjZ5M{G0PVA9N2F-
Rosetta2 DE3 NYT6UohjTnWwY4Tpc44h[XO|YYm= Ml;lN|AhdWmwcx?= MlHnTY5pcWKrdHnvckBw\iCIQV2tcIFj\WynZDDaRmEzPDhiYnnu[Ilv\yC2bzDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGhqezZvdHHn[4VlKEKURESgZpJwdW:mb33hbY4hOiBqM{OzJJRwKDR4MDDy[ZNq\HWnczmg[ZhxemW|c3XkJIlvKFKxc3X0eIEzKESHMzDj[YxteyCjZoTldkA{OCCvaX7zJIJ6KE[ub4Xy[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO|YYmsJGtqKD1iMD6wNlMh|ryPLh?= M2TNWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NE[zOFg4Lz5{OES2N|Q5PzxxYU6=
Rosetta2 DE3 MkLPSpVv[3Srb36gZZN{[Xl? M{XUdlMxKG2rboO= M3myeWlvcGmkaYTpc44hd2ZiRlHNMYxi[mWuZXSgXmJCOjR6IHLpcoRqdmdidH:gdoVkd22kaX7hcpQhcHWvYX6gUk11\XKvaX7hcEBJcXN4LYTh[4dm\CCEUlS0JIJzd22xZH;tZYlvKDFiKES0JJRwKDF4ODDy[ZNq\HWnczmg[ZhxemW|c3XkJIlvKFKxc3X0eIEzKESHMzDj[YxteyCjZoTldkA{OCCvaX7zJIJ6KE[ub4Xy[ZNk\W6lZTDwc4xiemm8YYTpc44h[XO|YYmsJGtqKD1iMD6wOFY1KM7:TT6= MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR4M{S4O{c,Ojh2NkO0PFc9N2F-
Rosetta2 DE3 NYnjXohrTnWwY4Tpc44h[XO|YYm= MV2zNEBucW6| NVToS2NJUW6qaXLpeIlwdiCxZjDGRW0udGGkZXzl[EBbSkF{NEigZolv\GmwZzD0c{Bz\WOxbXLpcoFvfCCqdX3hckBPNXSncn3pcoFtKEirc{[teIFo\2WmIFLSSFQh[nKxbX;kc41icW5iMjCoN|M{KHSxIES2NEBz\XOrZIXld{kh\XiycnXzd4VlKGmwIGLvd4V1fGF{IFTFN{Bk\WyuczDh[pRmeiB|MDDtbY5{KGK7IF\sc5Vz\XOlZX7j[UBxd2yjcnn6ZZRqd25iYYPzZZktKEmFNUCgQUAxNjB5N{Wg{txONg>? NGTVT2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES2N|Q5Pyd-Mki0OlM1QDd:L3G+
MV4-11 M4jiWGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MWS0JIRigXN? M1[wWWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1XPC1zMTDj[YxteyCjZoTldkA1KGSjeYOgZpkhX1OWLUigZZN{[XluIFnDOVAhRSByLkC5N{DPxE1w NHnPR5Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OES2N|Q5Pyd-Mki0OlM1QDd:L3G+
Rosetta2 DE3 M2X1Z2Z2dmO2aX;uJIF{e2G7 MmXBN|AhdWmwcx?= NE\5eldKdmirYnn0bY9vKG:oIF\BUU1t[WKnbHXkJHpDSTJ2ODDibY5lcW6pIITvJJJm[2:vYnnuZY51KGi3bXHuJG4ufGW{bXnuZYwhUGm|Nj30ZYdo\WRiQmLEOEBjem:vb3TvcYFqdiBzIDi0OEB1dyBzNkigdoV{cWS3ZYOpJIV5eHKnc4Pl[EBqdiCUb4PleJRiOiCGRUOgZ4VtdHNiYX\0[ZIhOzBibXnud{BjgSCIbH;1doV{[2WwY3WgdI9t[XKrenH0bY9vKGG|c3H5MEBKSzVyIE2gNE4yPDVizszNMi=> NXzofJBvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki0OlM1QDdpPkK4OFY{PDh5PD;hQi=>
MOLM13 MmPLS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2njflQh\GG7cx?= NYmxd|hXT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OTUGzJINmdGy|IHHmeIVzKDRiZHH5d{BjgSCZU2StPEBie3OjeTygTWM2OCB;IECuNlQyKM7:TT6= MlzPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh2NkO0PFcoRjJ6NE[zOFg4RC:jPh?=
TY82 Mk[1RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MXi3NkBpenN? M4foTWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVGm4NkBk\WyuczDh[pRmeiB5MjDodpMh[nliQ1PLPEBie3OjeTygTWM2OCB;IECuNkDPxE1w NVrSO|B7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1PFY4OThpPkK4OVg3PzF6PD;hQi=>
MM1S M2jXS2FvfGmycn;sbYZmemG2aY\lJIF{e2G7 NGS3[Xo4OiCqcoO= MU\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2PMWOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOFS{igZZN{[XluIFnDOVAhRSByLkKzJO69VS5? NYXmW|QzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki1PFY4OThpPkK4OVg3PzF6PD;hQi=>
BL21 (DE3)-codon plus-RIL MoL5SpVv[3Srb36gZZN{[Xl? NEfScXU1KGi{cx?= NUPDTmQ4UW6qaXLpeIlwdiCxZjDKVVEuTkmWQzDibY5lcW6pIITvJGhqezZvdHHn[4VlKEKUREStRmQyKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIFXzZ4hmemmlaHnhJINwdGliQlyyNUApTEV|KT3jc4RwdiCybIXzMXJKVCClZXzsd{BqdmO3YnH0[YQhcW5iZHHyb{Bnd3JiNDDodpMh[nliZnz1c5Jme2OnbnPlJIFvcXOxdILvdJkh[XO|YYmsJGlEPTBiPTCwMlI3KM7:TT6= M{npe|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NUi2O|E5Lz5{OEW4OlcyQDxxYU6=
THP1 MVfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MUnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFSKUEGgZ4VtdHNuIFnDOVAhRSByLkK5JO69VS5? M1rITFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUO5NVIyLz5{OEmzPVEzOTxxYU6=
TY82 MWLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFS\OEKgZ4VtdHNuIFnDOVAhRSByLkO5JO69VS5? MorHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7M{mxNlEoRjJ6OUO5NVIyRC:jPh?=
NALM16 MYnDfZRwfG:6aXPpeJkh[XO|YYm= M1vGUFUh\GG7cx?= NEHmU4JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPSUyPMU[gZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIFnfGW{IEWg[IF6eyCkeTDD[YxtXGm2ZYKtS4xwKGG|c3H5MEBGSzVyIE2gNE4zPyEQvF2u MoWyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjlzN{CwNlQoRjJ7MUewNFI1RC:jPh?=
NALM6 NFnEcFVEgXSxdH;4bYNqfHliYYPzZZk> NVLafmxiPSCmYYnz NEHoWJlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPSUyPNjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[2WubDD2bYFjcWyrdImgZYZ1\XJiNTDkZZl{KGK7IFPlcIxVcXSncj3HcI8h[XO|YYmsJGVEPTBiPTCwMlM6KM7:TT6= M{WxPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUewNFI1Lz5{OUG3NFAzPDxxYU6=
697 NGfqT|ZEgXSxdH;4bYNqfHliYYPzZZk> NXrm[Wc3PSCmYYnz Mk\zR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gOlk4KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA2KGSjeYOgZpkhS2WubGTpeIVzNUeubzDhd5NigSxiRVO1NEA:KDFwMUeg{txONg>? M3TPT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUewNFI1Lz5{OUG3NFAzPDxxYU6=
HD-MB03 MVHDfZRwfG:6aXPpeJkh[XO|YYm= MVi1JIRigXN? NUXNXI5jS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUERvTVKwN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOUBl[Xm|IHL5JGNmdGyWaYTldk1IdG9iYYPzZZktKEWFNUCgQUA{NjVizszNMi=> M3vpUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUewNFI1Lz5{OUG3NFAzPDxxYU6=
A673 M1HGd5FJXFNiYYPzZZk> MnmydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN? NXnKd29uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY NEHjOWZyUFSVIHHzd4F6 MnXYdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN? NGixUYM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Saos-2 MXTxTHRUKGG|c3H5 M1jTb5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO= MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
BT-37 NI\RelRyUFSVIHHzd4F6 NF:4Wm1yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN|ch[2WubIO= MnzWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
RD NWe0NJhLeUiWUzDhd5NigQ>? NXTMcJZ1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLEJINmdGy| NVT6XlZGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R) NHrqTGNyUFSVIHHzd4F6 MnW0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy| NYfQSGhSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643 NHWyZZlyUFSVIHHzd4F6 MkDkdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?= NEnSVVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
OHS-50 MUfxTHRUKGG|c3H5 MUnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| NG\Re|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh41 NVLoc3VneUiWUzDhd5NigQ>? MnLSdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SJ-GBM2 NVuyWVgzeUiWUzDhd5NigQ>? NXnBOWhHeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPKMWdDVTJiY3XscJM> M{DiNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC MlXldWhVWyCjc4PhfS=> NXzLZppweUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM> NVTCfJFTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 MoC1dWhVWyCjc4PhfS=> M3nkbpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQj3FRoMyKGOnbHzz MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
LAN-5 NV7tNlhpeUiWUzDhd5NigQ>? NF;n[WxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
TY82 NXvrdGx6SW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= M1XvSlczKGi{cx?= MoXGRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCWWUiyJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCFQ1u4JIF{e2G7LDDJR|UxKD1iMD6zNFQ{KM7:TT6= NILTT409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWyOVQ{PSd-Mkm1NlU1OzV:L3G+
MM1S Ml3lRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NVXpVVc3PzJiaILz MWrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2PMWOgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KEOFS{igZZN{[XluIFnDOVAhRSByLkO0PVIh|ryPLh?= MmL4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MkW0N|UoRjJ7NUK1OFM2RC:jPh?=
TY82 MlXaSpVv[3Srb36gZZN{[Xl? MYCwMlIhfG9iMTD1US=> NUnze2k6OjRiaILz NHjLTJRKdmirYnn0bY9vKG:oIFLSSFQhcW5iaIXtZY4hXFl6MjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h[y2PeXOgdJJwfGWrbjDlfJBz\XO|aX;uJIF1KDBwMjD0c{AyKHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgZY5idHm|aYO= MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV{NUSzOUc,Ojl3MkW0N|U9N2F-
TY82 NGHTfWhHfW6ldHnvckBie3OjeR?= NHv6TIoxNjJidH:gNUB2VQ>? NIPrUIozPCCqcoO= MnnkTY5pcWKrdHnvckBw\iCEUlS0JIlvKGi3bXHuJHR[QDJiY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJIMuVXmlIH3SUmEh\XiycnXzd4lwdiCjdDCwMlIhfG9iMTD1UUBi\nSncjCyOEBpenNiYomgVnQuWEOUIHHuZYx6e2m| MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV{NUSzOUc,Ojl3MkW0N|U9N2F-
TY82 or NCI-H1299 NWLJWVdoTnWwY4Tpc44h[XO|YYm= NXfvVlFwOC5{IITvJFEhfU1? NXLMclVuOjRiaILz MX3Jcohq[mm2aX;uJI9nKEKURESgbY4hcHWvYX6gWHk5OiCxcjDOR2kuUDF{OUmgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKFCGLVyxJJBzd3SnaX6g[ZhxemW|c3nvckBifCByLkKgeI8hOSC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JIFv[Wy7c3nz MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV{NUSzOUc,Ojl3MkW0N|U9N2F-
TY82 or NCI-H1299 NV[5[|VPTnWwY4Tpc44h[XO|YYm= NV;iWFhWOC5{IITvJFEhfU1? MmfwNlQhcHK| M{fOdGlvcGmkaYTpc44hd2ZiQmLEOEBqdiCqdX3hckBVYTh{IH;yJG5EUS2KMUK5PUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iUFStUFEhdVKQQTDlfJBz\XO|aX;uJIF1KDBwMjD0c{AyKHWPIHHmeIVzKDJ2IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZM> MnjyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MkW0N|UoRjJ7NUK1OFM2RC:jPh?=
C4-2B MkDqRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? NXuxd2dIQTZiaILz MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEN2LULCJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCFZXzsMXRqfGW{IHfsc{Bz\WGpZX70JIJie2WmIHz1cYlv\XOlZX7j[UBie3OjeR?= M{HEOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUSxN|cyLz5{OUW0NVM4OTxxYU6=
22Rv1 MYrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MUK5OkBpenN? M2nrbWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iMkLSelEh[2WubIOgZYZ1\XJiOU[gbJJ{KGK7IFPlcIwuXGm2ZYKg[4xwKHKnYXflcpQh[mG|ZXSgcJVucW6nc3PlcoNmKGG|c3H5 NVHiR4F[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OFE{PzFpPkK5OVQyOzdzPD;hQi=>
LNCAP MkPnRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? M{fDT|k3KGi{cx?= NYG4b21USW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDMUmNCWCClZXzsd{Bi\nSncjC5OkBpenNiYomgR4VtdC2WaYTldkBodG9icnXh[4VvfCCkYYPl[EBtfW2rbnXzZ4Vv[2ViYYPzZZk> MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV2MUO3NUc,Ojl3NEGzO|E9N2F-
HL60 NGTubppEgXSxdH;4bYNqfHliYYPzZZk> M2f2[2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhNPjBiY3XscJMh[nliTWTTJIF{e2G7LDDJR|UxKD1iMD6xNkDPxE1w MmG5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl4NUewPVkoRjJ7NkW3NFk6RC:jPh?=
Raji NEC5boVHfW6ldHnvckBie3OjeR?= NYLiSmY5UW6qaXLpeIlwdiCxZjDCVmQ1NUKGMTDpckBpfW2jbjDSZYpqKGOnbHzzJIF{e2W|c3XkJIF{KGSxd37y[Yd2dGG2aX;uJI9nKE2\QzDn[Y5mKGW6cILld5Nqd25iYomgVGNTKG2ndHjv[EwhUUN3MDC9JFAvOTN{IN88UU4> NGPkeGM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OU[1O|A6QSd-Mkm2OVcxQTl:L3G+
LNCAP NVTqb3ZJSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NHrvNJFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzOR2FRKGOnbHzzMEBKSzVyIE2gNE4{PTZ3IN88UU4> NV;MW3ZqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm3OVg2OThpPkK5O|U5PTF6PD;hQi=>
MV411 MVXDfZRwfG:6aXPpeJkh[XO|YYm= NUDoZVl7PzJiaILz M{POfmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1XPDFzIHPlcIx{KGGodHXyJFczKGi{czDifUBE\WyuVHn0[ZIuT2yxIHHzd4F6NCCLQ{WwJF0hOC56IN88UU4> NFnKTZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEK2PFcxOid-M{CyOlg4ODJ:L3G+

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Growth inhibition assay
Cell viability ; 

PubMed: 26840085     


A., B. and C. Dose response curves of MPNST-derived cell lines treated with three bromodomain inhibitors: JQ1, OTX015 and I-BET-762.

26840085
In vivo I-BET-762 confers protection against lipopolysaccharide-induced endotoxic shock and bacteria induced sepsisa. Single dose of I-BET applied at 1.5 h after LPS injection cures the mice. Twice-daily injections of I-BET for 2 days protects mice against death caused by sepsis. [1] Limited treatment with I-BET-762 exclusively during early priming inhibited the ability of Th1-differentiated 2D2 T cells to induce neuroinflammation in a mouse model of experimental autoimmune encephalomyelitis (EAE). [2]

Protocol

Kinase Assay:[1]
- Collapse

Fluorescence resonance energy transfer (FRET) titrations:

Fluorescence resonance energy transfer (FRET) titrations. I-BET is titrated against BRD2 (200 nM), BRD3 (100 nM) and BRD4 (50 nM) in 50 mM HEPES pH7.5, 50 mM NaCl, 0.5 mM CHAPS in the presence of tetra-acetylated Histone H4 peptide (200 nM). After equilibrating for 1 hour, the bromodomain protein : peptide interaction is detected using FRET following the addition of 2nM Europium cryptate labelled streptavidin and 10 nM XL-665-labelled anti-6His antibody in assay buffer containing 0.05% (v/v) BSA and 400 mM KF. Plates are read using an Envision Plate reader (excitation 320 nm, emission 615 nm and 665 nm).
Cell Research:[2]
- Collapse
  • Cell lines: CD4+ T cells
  • Concentrations: ~500 nM
  • Incubation Time: 60–72 h
  • Method: CD4+ T cells are isolated from lymph nodes and spleens of 10- to 12-wk old mice and activated with plate bound anti-CD3 and anti-CD28 antibodies in the presence of indicated cytokines. I-BET-762 compounds is included during the 60–72 h of initial activation. Over the course of 5 d of T-cell culture and expansion, the compounds is diluted 12-fold relative to the starting concentrations.
    (Only for Reference)
Animal Research:[1]
- Collapse
  • Animal Models: Mouse
  • Dosages: 30 mg/kg
  • Administration: i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (198.15 mM)
Ethanol 42 mg/mL warmed (99.07 mM)
Water Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 423.9
Formula

C22H22ClN5O2

CAS No. 1260907-17-2
Storage powder
in solvent
Synonyms GSK525762, GSK525762A
Smiles CCNC(=O)CC1C2=NN=C(N2C3=C(C=C(C=C3)OC)C(=N1)C4=CC=C(C=C4)Cl)C

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03266159 Withdrawn Drug: GSK525762 Besylate tablets|Drug: Trametinib tablets Solid Tumours GlaxoSmithKline November 27 2017 Phase 2
NCT02964507 Active not recruiting Drug: GSK525762|Drug: Placebo|Drug: Fulvestrant Neoplasms GlaxoSmithKline February 2 2017 Phase 1
NCT01943851 Completed Drug: GSK525762 Neoplasms GlaxoSmithKline May 14 2014 Phase 2
NCT01587703 Completed Drug: GSK525762 Carcinoma Midline GlaxoSmithKline March 28 2012 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Epigenetic Reader Domain Signaling Pathway Map

Epigenetic Reader Domain Inhibitors with Unique Features

Tags: buy Molibresib (I-BET-762) | Molibresib (I-BET-762) supplier | purchase Molibresib (I-BET-762) | Molibresib (I-BET-762) cost | Molibresib (I-BET-762) manufacturer | order Molibresib (I-BET-762) | Molibresib (I-BET-762) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID